Manufacturers Push for Documented Piperine Purity Standards
Pharmaceutical manufacturers replacing inconsistent bulk-commodity programs under mounting purity-verification pressure are increasingly specifying processors with documented piperine-purity certification standing over uncertified equivalents in vendor selection decisions across most major premium-focused programs. Olam and McCormick have both expanded certified purity-testing capacity over the past two years to serve this growing procurement demand. At least a dozen major manufacturers have qualified new certified piperine-purity partnerships since 2023, and processors report this shift is meaningfully expanding addressable procurement demand across multiple program categories, with several additional manufacturers evaluating comparable programs soon across additional premium markets internationally.
Market Impact: Sustains 4%+ deployment-linked growth yearly








